🔗 Computational Design of a TCR-like Human VH Domain Antibody That Specifically Recognizes a WT1-Derived Peptide Presented by Class I Major Histocompatibility Complex. doi.org/10.34133/csb...

📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

@csbj.org #CancerImmunotherapy #Oncology

University of California, Los Angeles (UCLA) (@ucla.edu) is hiring:
Postdoctoral Scholar in RNA-Lipid Nanoparticle Cancer Immunotherapy

#postdoc #medicine #cancerimmunotherapy

How can nanoscale design overcome biological barriers in cancer treatment?

📅 Join the 2026 Westlake × @science.org Symposium #4: Nanoscale Therapeutics on Oct. 22 at 8:00 AM ET.

Register: https://bit.ly/4yQnFau

#Nanomedicine #CancerImmunotherapy

Introducing our new feature, AJT Catalyst!
buff.ly/HlAxrBr
This month, read "Antibody-cytokine fusion enables spatially targeted modification of immune responses to tumors" by EM Gillis Buck et al
buff.ly/Iq1f7NT
#Immunotherapy #Cytokines #CancerImmunotherapy

🧬 A novel lipopeptide suppressed both melanoma & psoriasis in immunocompetent mice. Findings suggest it may help balance anticancer immunity and immune tolerance, offering a potential new approach in cancer immunotherapy. ⚖️ #CancerImmunotherapy
www.mdpi.com/2227-9059/13...

Orca-T represents a milestone in cancer research, making stem cell transplants safer for blood cancer patients by using the immune system with greater precision to open new possibilities across oncology.

Learn more: med.stanford.edu/cancer/about...

#StanfordMedicine #CancerImmunotherapy

Researchers evaluate the novel PARP inhibitor prodrug TSL-1502 in a phase 2 trial, demonstrating promising antitumor activity in BRCA-mutated HER2-negative advanced breast cancer. #ClinicalTrial

#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #CancerImmunotherapy

6/ 💡 Together, the study expands the landscape of potential HCC antigens beyond the canonical proteome and provides a framework for discovering and validating ncORF-derived targets for cancer immunotherapy.

#LiverCancer #HCC #CancerImmunotherapy #Immunopeptidomics

Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade.

#TcellExhaustion #CheckpointBlockade #TumorImmunology #CD8Tcells #AntiPD1 #Tpex #ImmuneCheckpoint #CancerImmunotherapy

🧬 Natural product immunotherapies in 3D tumor models—penetration vs activity. This review says: don't chase depth, preserve activity at peripheral immune cells. New evaluation framework inside!

📌 www.mdpi.com/1999-4923/17...

#CancerImmunotherapy #NaturalProducts #3DModels

Better #CancerImmunotherapy requires tackling hidden immune barriers.
This review highlights how dysfunctional #Bcells suppress anti-tumor immunity and outlines strategies to reprogram the #TumorMicroenvironment.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...

The transcription factor IRF8 drives tumor-specific exhaustion in CD8⁺ T Cells. From Marco Ongaro, Grégory Verdeil and colleagues: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

Which noncanonical tumor antigens can be translated into T-cell targets?

EVA003 emerges as a #Melanoma-enriched antigen whose HLA-A*03:01-presented peptide is recognized by a natural TCR that directs melanoma cell killing.

#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerImmunotherapy

Intravesical mesothelin-based #CARTcells targeting MUC16 effectively control #BladderCancer in preclinical models. From Parwiz Abrahimi, Renier Brentjens, Jedd Wolchok, Taha Merghoub et al.: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@ostendorflab.org, @immushuang.bsky.social, @sohailtavazoie.bsky.social et al. show that activation of LXRs elicits a T cell "pre-effector" state that enhances priming and promotes anti-tumor immunity. rupress.org/jem/article/...

In #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia